… Oral/GI mucositis is a common side effect of many anticancer therapies. Evidence‐based
clinical practice guidelines are presented as a benchmark for clinicians to use for routine …

… Mucositis is defined as inflammatory lesions of the oral and/or gastrointestinal tract caused
by high-dose cancer therapies… Alimentary tract mucositis refers to the expression of mucosal …

… , mucositis following targeted anticancer therapies has been … , mucositis following targeted
anticancer therapies has been … Oral mucositis occurs in approximately 20–40% of patients …

… This, of course, reduces the efficacy of anti-cancer therapy, as some neoplastic cells will
also survive or recover. Furthermore, it may not be a practical option, particularly when salvage …

… Conversely, when capecitabine is associated to irinotecan (XELIRI regimen), a
topoisomerase 1 inhibitor, it induces higher gastro-intestinal mucositis (GIM) events compared to …

… It has been shown to reduce gastrointestinal mucositis in animals receiving chemotherapy.
Results in human trials have been mixed. AES-14, which is glutamine in a vehicle that greatly …

… The development of biologically based targeted cancer therapies, which aim to block the
growth… , and management of oral mucositis associated with conventional cytotoxic therapies for …

… covers the management of oral mucositis; we do not specifically cover distal GI tract … In
conclusion, mucositis is a common adverse effect of anticancer therapy and can contribute …

… Until now, clinicians have dealt with chemotherapy-associated and radiation-associated
mucositis through alteration in cancer therapy protocols (eg, using alternative regimens or …

… It may drastically affect cancer treatment as well as the patient’s quality of life. The incidence
… of mucositis will vary from patient to patient. It will also vary from treatment to treatment. It is …